Full-Time

Business Development Representative

Confirmed live in the last 24 hours

Certara

Certara

1,001-5,000 employees

Biosimulation and data science solutions provider

No salary listed

Junior

Berlin, Germany

Category
Business Development
Business & Strategy
Required Skills
Sales
Lead Generation
Word/Pages/Docs
Salesforce
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in business or within a science related discipline
  • 1-2 years as a lead generation representative, preferably within the pharmaceutical industry
  • Attention to detail for capturing all prospect interaction notes into Salesforce
  • Experienced in the MS Office suite (Excel/Word/PPT)
  • Excellent verbal and written communication skills
  • Strong organizational skills with the ability to multi-task and set priorities
  • Ability to work in a high energy team environment
  • Must be capable of communicating value propositions for software and services to effectively identify opportunities
  • Ability to support bookings pipeline forecasts for account executives
  • Self-motivated professional with ability to work with minimal supervision in a team environment
Responsibilities
  • Meet/exceed Sales Assigned and Sales Qualified Lead goals on a weekly and monthly basis
  • Meet/exceed Key Performance Indicator (KPI) metrics on daily/weekly prospecting activities (100 blended activities daily 50 calls / 50 emails)
  • Document all activities (phone and email outreach)
  • Qualify prospects to the correct agreed upon criteria with the sales organization
  • Host Hand-off calls with prospects and the sales team
  • Develop and maintain superior relationships with prospects and customers
  • Build a strong pipeline to support assigned software quotas to account executives
  • Gather market intelligence and relay to management in order to improve offerings and communication for various market needs

Certara provides biosimulation and data science solutions to enhance drug development and regulatory submissions. Their products include software and consulting services that help pharmaceutical and biotechnology companies, as well as regulatory agencies, make better decisions throughout the drug development process. Certara's software allows users to simulate biological processes and visualize data, which aids in improving the efficiency and success rates of clinical trials. Unlike many competitors, Certara combines advanced technologies like deep learning and artificial intelligence in their offerings. The company's goal is to optimize the drug development lifecycle, making it more effective and successful.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Princeton, New Jersey

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Chemaxon enhances Certara's cheminformatics capabilities for drug discovery.
  • Biosimulation market projected to grow, boosting demand for Certara's solutions.
  • AI-enabled CoAuthor platform reduces time and costs in regulatory submissions.

What critics are saying

  • Emerging biosimulation companies may erode Certara's market share with competitive solutions.
  • Rapid AI advancements could outpace Certara's current software capabilities.
  • Integration challenges with Chemaxon may delay acquisition benefits.

What makes Certara unique

  • Certara leads in biosimulation and data science for drug development optimization.
  • Phoenix™ 8.5 is the gold standard in PK/PD modeling, used by top pharma companies.
  • CoAuthor platform integrates AI to streamline medical writing, enhancing efficiency and quality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

-3%
Stock Titan
Mar 5th, 2025
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Certara (NASDAQ: CERT) has appointed Dr. Adrian McKemey as President of Drug Development Solutions, effective March 3rd, 2025.

Hit Consultant
Jan 17th, 2025
Recent Digital Health Executive Hires And Promotions: Medidata Expands Team, Carerev, Philips, Eko Health, Others

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

PharmiWeb
Oct 18th, 2024
Biosimulation Market to Grow at a CAGR of 21.5% During the Ensuing Ten years, Reaching USD 20.9 Billion by the end of 2032.

In June 2022, Certara announced its new version of Biosimulation software for the progress of Novel Biologics.

Certara
Oct 16th, 2024
Certara Appoints John Reynders as New Independent Board Member

Certara appoints John Reynders as new independent board member.

GlobeNewswire
Aug 15th, 2024
Certara Launches Phoenix(Tm) Version 8.5 Drug Development Software

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S